ALS Treatment Strategies
Overview <table class="infobox infobox-therapeutic">
...
ALS Treatment Strategies
Overview <table class="infobox infobox-therapeutic">
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting upper and lower motor [neurons](/entities/neurons), leading to muscle weakness, paralysis, and respiratory failure. Treatment strategies span symptomatic management, disease-modifying therapies, and emerging approaches targeting underlying molecular mechanisms. This page provides a comprehensive overview of current and developing ALS treatments. [@bensimon1994]
FDA-Approved Disease-Modifying Therapies
Riluzole (Rilutek)
Mechanism : Sodium channel blocker; glutamate excitotoxicity reductionDose : 50 mg twice dailyEfficacy : Extends survival by 2-3 months; modest functional benefitStatus : First FDA-approved ALS drug (1995)Edaravone (Radicava)
Mechanism : Free radical scavenger; reduces oxidative stressDose : 60 mg IV infusion (10 days/month after loading)Efficacy : Slows functional decline (33% reduction in ALSFRS-R decline)Status : FDA-approved (2017)AMX0035 (Relyvrio)
Mechanism : Combination of sodium phenylbutyrate and taurursodiolEfficacy : Extended survival by 4.8 months; functional benefitDose : 1 packet daily (dissolved in water)Status : FDA-approved (2022)Tofersen (Qalsody)
Mechanism : Antisense oligonucleotide targeting SOD1 geneDose : 100 mg intrathecal injection every 2 weeks (4 doses, then monthly)Efficacy : Reduces SOD1 protein and [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain; functional benefit in SOD1 patientsStatus : FDA-approved (2023) for SOD1-ALSSymptomatic Treatments
Muscle Spasticity
Baclofen : GABA-B agonist; start 5-10 mg TID, titrate to 30-60 mg/dayTizanidine : Alpha-2 adrenergic agonist; 2-8 mg TIDBenzodiazepines : Diazepam or clonazepam for severe spasticityMuscle Cramps
Quinine sulfate : 200-300 mg at bedtimeMagnesium supplements : 250-500 mg dailyPhysical therapy : Stretching exercisesSalivation
Glycopyrrolate : 1-2 mg TIDScopolamine patch : 1.5 mg patch every 72 hoursBotulinum toxin : For refractory droolingDysarthria and Dysphagia
Speech therapy : Augmentative communication devicesSwallowing assessments : Prevent aspirationDiet modifications : Thickened liquids, modified texturesRespiratory Support
Non-invasive ventilation (NIV) : BiPAP for nocturnal hypoventilationAssistive cough devices : Mechanical insufflation-exsufflationMechanical ventilation : For advanced diseaseEmerging Disease-Modifying Therapies
Gene Therapies
Neuroprotective Agents
Anti-Aggregation Strategies
Small molecules : Targeting [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates[Autophagy](/entities/autophagy) enhancers : Rapamycin, trehaloseAntibodies : Anti-aggregate immunotherapiesStem Cell Therapies
Neural stem cells : Phase 1/2 trials ongoingMSC therapy : Immunomodulation; Phase 2 trialsiPSC-derived motor neurons : PreclinicalClinical Trials Landscape
Active Phase 3 Trials
Biomarkers in Development
Neurofilament light chain (NfL) : Blood biomarker for disease progressionALS-related proteins : SOD1, TDP-43, FUS in CSFNeuroimaging : PET and MRI for disease monitoringMulti-Disciplinary Care
Standard of Care Components
Neurology : Disease management and medicationPulmonology : Respiratory assessment and supportPhysical therapy : Mobility and functionOccupational therapy : Daily activities adaptationSpeech therapy : Communication and swallowingNutrition : Dietary support and PEG placementPsychology : Mental health supportSocial work : Care coordination
Clinical Guidelines
EFNS Guidelines : European evidence-based guidelinesAAN Practice Parameters : American Academy of NeurologyInternational Alliance : ALS caregiver guidelinesPatient Stratification
Genetic Subtypes
SOD1-ALS : 15-20% of familial cases; tofersen approvedC9orf72-ALS : Most common genetic form (40% familial)FUS-ALS : 5% of familial casesSporadic ALS : 90-95% of cases; no identified mutationPersonalized Medicine Approaches
Genetic testing : Increasingly recommended at diagnosisPhenotypic subtyping : Bulbar vs. limb onsetBiomarker stratification : NfL levels for trial enrichmentSee Also
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Riluzole](/therapeutics/riluzole)
[Edaravone](/therapeutics/edaravone)
[Antisense Oligonucleotide Therapy](/therapeutics/antisense-oligonucleotide-therapies)
[Motor Neuron Disease](/diseases/motor-neuron-disease)
[Excitotoxicity](/mechanisms/excitotoxicity)
External Links
[PubMed: ALS Treatment Strategies](https://pubmed.ncbi.nlm.nih.gov/?term=amyotrophic+lateral+sclerosis+treatment)
[ClinicalTrials.gov](https://clinicaltrials.gov)
[ALS Association](https://www.als.org/)
[ALS Therapy Development Institute](https://www.als.net/)
References
[Bensimon et al., Riluzole in ALS (1994) (1994)](https://doi.org/10.1016/S0140-6736(94)
[Sawada et al., Edaravone in ALS (2017) (2017)](https://doi.org/10.1001/jamaneurol.2017.0507)
[Paganoni et al., AMX0035 Trial (2020) (2020)](https://doi.org/10.1056/NEJMoa2002244)
[Miller et al., Tofersen for SOD1-ALS (2022) (2022)](https://doi.org/10.1056/NEJMoa2204705)
[Van Es et al., ALS disease modification (2023) (2023)](https://doi.org/10.1016/S0140-6736(23)
[Hardiman et al., ALS clinical management (2021) (2021)](https://doi.org/10.1038/s41582-021-00556-0)
Unknown, NCT05686534 Clinical Trial (n.d.)
[Lu et al., C9orf72 ASO therapy (2022) (2022)](https://doi.org/10.1038/s41593-022-01074-8)
[Benatar et al., Neurofilament biomarkers (2023) (2023)](https://doi.org/10.1016/S1474-4422(23)
[Goutman et al., Recent advances in ALS (2022) (2022)](https://doi.org/10.1016/j.neuron.2022.09.014)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
[Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: FOXO1
[Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
[Perforant Path Presynaptic Terminal Protection Strategy](/hypothesis/h-76888762) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: PPARGC1A
[Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
[Chaperone-Mediated APOE4 Refolding Enhancement](/hypothesis/h-637a53c9) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: HSPA1A, HSP90AA1, DNAJB1, FKBP5
[Metabolic Circuit Breaker via Lipid Droplet Modulation](/hypothesis/h-3d993b5d) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: PLIN2
Related Analyses:
[Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) 🔄
Show full description